Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $134

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $128 to $134.

Benzinga · 11/20/2019 15:03

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $128 to $134.